<DOC>
	<DOC>NCT00988494</DOC>
	<brief_summary>Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.</brief_summary>
	<brief_title>Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Has corneal epithelial defect and decreased corneal sensitivity. Has undergone continuous treatment for corneal epithelial defect for 1 week or longer. Presence of disease such as active ocular infection, or abnormal lid closure. History or presence of chemical burn, Stevens Johnson Syndrome, etc. History of corneal transplantation, LASIK, or hematopoietic stem cell transplantation.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>